Volume 22 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(1): 64-69
LIU Wei, ZHANG Yiyin, ZHAO Fang, HU Zhiguo, WANG Ya. The efficacy and prognostic markers of anti-PD-1 immunotherapy combined with anti-angiogenic therapy for advanced hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2024, 22(1): 64-69. doi: 10.16766/j.cnki.issn.1674-4152.003332
Citation: LIU Wei, ZHANG Yiyin, ZHAO Fang, HU Zhiguo, WANG Ya. The efficacy and prognostic markers of anti-PD-1 immunotherapy combined with anti-angiogenic therapy for advanced hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2024, 22(1): 64-69. doi: 10.16766/j.cnki.issn.1674-4152.003332
shu

The efficacy and prognostic markers of anti-PD-1 immunotherapy combined with anti-angiogenic therapy for advanced hepatocellular carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003332
  • 1.

    Department of Oncology, Huaibei People's Hospital, Huaibei, Anhui 235000, China

Funds:

 1908085QH333

  • Received Date: 2023-05-16
    Available Online: 2024-03-09
    Abstract
  •   Objective  To evaluate the efficacy and safety of anti-PD-1 immunotherapy combined with anti-angiogenic therapy in the treatment of advanced hepatocellular carcinoma and to explore the potential prognostic factors.  Methods  We collected the clinical data of patients with advanced hepatocellular carcinoma who were treated with PD-1 inhibitors combined with anti-angiogenic therapy from March 2020 to December 2022 in Huaibei People's Hospital and observed the clinical efficacy, adverse events. Kaplan-Meier was used to analyze the survival benefit. Univariate and multivariate Cox analysis were performed to evaluate the association between prognostic factors and survival outcomes.  Results  Among the 55 patients enrolled in this study, the objective response rate was 18.2% (10/55) and the disease control rate was 74.5% (41/55). Survival analysis showed that the median progression-free survival (mPFS) was 8.5 months and the median overall survival (mOS) was 17.4 months. Patients who received transcatheter arterial chemoembolization (TACE) had better PFS and OS than those who did not (P < 0.005). PFS and OS were longer in patients with lower NLR (mPFS: 10.1 months vs. 6.5 months; mOS: 18.6 months vs. 14.9 months, P < 0.05). The most common adverse events were fatigue, hypertension, etc. 11 patients experienced grade 3-4 adverse events.  Conclusion  In this real-world study, anti-PD-1 immunotherapy combined with anti-angiogenic therapy could significantly prolong the survival of advanced HCC patients, especially in patients receiving TACE treatment, and the adverse events were controllable. The pre-treatment serum NLR level is an independent prognostic factor to predict PFS and OS, which could help to screen the potential patients who can benefit from immunotherapy.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    SUNG H, FERLAY J, SIEGRL R L, LAVERSANNEM, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. doi: 10.1016/S0140-6736(18)30010-2
    [3]
    陆海鹏. 索拉非尼治疗原发性肝癌的应用进展研究[J]. 中国医药指南, 2018, 16(19): 31-32. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201819021.htm

    LU H P. Advances in the application of sorafenib in primary hepatocellular carcinoma[J]. Guide of China Medicine, 2018, 16(19): 31-32. https://www.cnki.com.cn/Article/CJFDTOTAL-YYXK201819021.htm
    [4]
    VOGEL A, QI S, KUDO M, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(8): 649-658. doi: 10.1016/S2468-1253(21)00110-2
    [5]
    REN Z G, XU J M, BAI Y X, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. doi: 10.1016/S1470-2045(21)00252-7
    [6]
    XU J M, SHEN J, GU S Z, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. doi: 10.1158/1078-0432.CCR-20-2571
    [7]
    FINN R S, IKEDA M, ZHU A X, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. doi: 10.1200/JCO.20.00808
    [8]
    HACK S P, ZHU A X, WANG Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities[J]. Front Immunol, 2020, 11. DOI: 10.3389/fimmu.2020.598877.
    [9]
    LI B, YAN C, ZHU J, et al. Anti-PD-1/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review[J]. Front Immunol, 2020, 11: 1037. DOI: 10.3389/fimmu.2020.01037.
    [10]
    WYKES M N, LEWIN S R. Immune checkpoint blockade in infectious diseases[J]. Nat Rev Immunol, 2018, 18(2): 91-104. doi: 10.1038/nri.2017.112
    [11]
    REN Z Z, YUE Y X, ZHANG Y W, et al. Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles[J]. Front Immunol, 2021. DOI: 10.3389/fimmu.2021.624789.
    [12]
    LI X W, FU Z G, CHEN X X, et al. Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China Real-World[J]. Front Oncol, 12: 950266. DOI: 10.3389/fonc.2022.950266.
    [13]
    WEI D, XUE Z X, YAN Q, et al. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a meta-analysis[J]. Medicine, 2018. DOI: 10.1097/MD.0000000000013301.
    [14]
    GUAN X Q, LU Y Y, ZHU H P, et al. The crosstalk between cancer cells and neutrophils enhances hepatocellular carcinoma metastasis via neutrophil extracellular traps-associated cathepsin g component: a potential therapeutic target[J]. J Hepatocell Carcinoma, 2021, 8: 451-465. doi: 10.2147/JHC.S303588
    [15]
    杨丽萍, 吴爱林, 周燕, 等. 放疗前NLR和PLR对局部晚期鼻咽癌患者预后的影响[J]. 中华全科医学, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622

    YANG L P, WU A L, ZHOU Y, et al. Effect of NLR and PLR from pre-radiotherapy on the prognosis of locally advanced nasopharyngeal carcinoma patients[J]. Chinese Journal of General Practice, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622
    [16]
    HONG J Y, CHO H J, SA J K, et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial[J]. Genome Med, 2022, 14(1): 1. DOI: 10.1186/s13073-021-00995-8.
    [17]
    CHEON J, YOO C, HONG J Y, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma[J]. Liver Int, 2022, 42(3): 674-681. doi: 10.1111/liv.15102
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (81) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return